Details for Patent: 9,238,076

Which drugs does patent 9,238,076 protect, and when does it expire?

Patent 9,238,076 protects FARXIGA, BYDUREON, BYDUREON PEN, and BYDUREON BCISE, and is included in three NDAs.

Protection for BYDUREON has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-four patent family members in twenty-two countries.

Summary for Patent: 9,238,076

Title:	Polymer-based sustained release device
Abstract:	This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
Inventor(s):	Wright; Steven G. (Madeira, OH), Christensen; Troy (Mason, OH), Yeoh; Thean (Salem, CT), Rickey; Michael E. (Morrow, OH), Hotz; Joyce M. (Cincinnati, OH), Kumar; Rajesh (Marlborough, MA), Fineman; Mark (San Deigo, CA), Smith; Christine (San Diego, CA), Ong; John (San Diego, CA), Lokensgard; David M. (San Diego, CA), Costantino; Henry R. (Woodinville, WA)
Assignee:	Alkermes Pharma Ireland Limited (Dublin, IE) Amylin Pharmaceuticals, LLC (San Diego, CA)
Application Number:	13/743,117
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 9,238,076

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-001	Jan 8, 2014		RX	Yes	No						TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014		RX	Yes	Yes						TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012		DISCN	Yes	No					Y
Astrazeneca Ab	BYDUREON PEN	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-002	Feb 28, 2014		DISCN	Yes	No					Y

International Family Members for US Patent 9,238,076

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1734971		16/2012	Austria
European Patent Office	1734971		122012000028	Germany
European Patent Office	1734971		C300526	Netherlands
European Patent Office	1734971		CA 2012 00015	Denmark